Revvity Stock Climbs 21% On A 5-Day Winning Streak
A recent surge in the stock has drawn attention, but the underlying business metrics tell a different story.
Revvity (RVTY) stock has now moved higher for 5 consecutive trading days, gaining a cumulative 21%. That streak has added about $2.9 billion to the company’s market value, which now stands at about $16 billion. For anyone holding the stock, this recent run has been a significant event.
RVTY Versus The S&P 500, Streak And Beyond
Here is how RVTY stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | RVTY | S&P 500 |
|---|---|---|
| 1D | 0.7% | 1.1% |
| 5D (Current Streak) | 21.3% | 0.6% |
| 1M (21D) | 29.0% | -0.7% |
| 3M (63D) | 50.1% | 2.9% |
| YTD 2026 | 52.0% | 11.6% |
| 2025 | -13.1% | 16.4% |
| 2024 | 2.4% | 23.3% |
| 2023 | -21.9% | 24.2% |
Is The Rally Running Ahead Of The Fundamentals?
The stock’s move has been its own story, not the market’s. Over the same 5 trading days, the S&P 500 returned just +0.6%. While such streaks are not unique, with 7 other S&P 500 stocks on similar runs, the valuation context is notable. Revvity trades at a price-to-earnings multiple of 68.9, well above the 25.9 median for its Health Care sector peers. The surge followed back-to-back presentations at the Morgan Stanley and Baird healthcare conferences earlier in the week, where leadership outlined margin targets and cash-flow expectations.
The company’s recent growth and profitability also sit below sector medians. Revenue over the last twelve months grew 4.1%, compared to a median of 8.1% for S&P 500 Health Care stocks. Its operating margin is 12.3%, versus a median of 17.6%. The stock trades at about $146.73 a share as of 9/17/2026.
A Streak Is Information, Not An Instruction.
A multi-day move like this one is a clear signal of investor attention and momentum. It is not, by itself, a reason to buy or sell. The disciplined approach is to treat the new price as a question: does the business itself justify this valuation? The data here provides a starting point for that assessment.
A climb like this is worth respecting, and worth testing: the momentum that lasts is usually the kind management itself is underwriting. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.
Prefer the theme to this single name? Our ETF Scorecard shows how the health care funds stack up. Any one of those funds is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Momentum Is A Tailwind, Not A Plan
Riding a stock that rises every day feels effortless, and that is precisely the danger: the same momentum that built this run can reverse without notice, and one name’s reversal should never be able to reset your whole year.
That is what the Trefis High Quality (HQ) Portfolio is for: about 30 quality businesses screened for the fundamentals that survive momentum’s mood swings, held with rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Watch the runs; own the resilience.